Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Pharmacological Advances for Treatment in Hypertension 2.0
share announcement

Pharmacological Advances for Treatment in Hypertension 2.0

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2815

Special Issue Editor

Prof. Dr. Arquimedes Gasparotto Junior

E-Mail Website
Guest Editor
Laboratory of Cardiovascular Pharmacology (LaFaC), Federal University of Grande Dourados (UFGD), Dourados, Brazil
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Noncommunicable diseases, especially cardiovascular diseases are the main leading cause of morbidity and mortality worldwide. Hypertension is the main aggravating risk factors and can negatively impact the incidence, severity, and clinical course of several types of cardiovascular disease, directly contributing to a complex set of pathological interactions. The relationship between hypertension and other cardiovascular disorders can lead to a higher risk of undesirable outcomes in several patient groups. Moreover, hypertension is also considered an independent determinant of cardiovascular disease. Among the therapeutic options available to treat hypertension, synthetic drugs, as well as herbal medicines, stand out. Medicinal plants have been applied since ancient times and remain a significant therapeutic resource worldwide. Despite their widespread use, many compounds have not experienced careful scientific investigation, whether they are studies of efficacy, toxicity, or drug-to-drug interactions. In addition, there are systematic efforts to discover new therapeutic options for the prevention and treatment of hypertension.

In this Special Issue, we would like to invite investigators to submit preclinical or clinical studies focusing on the pharmacological advances for the treatment of hypertension

We will consider both original research and review articles.

Potential topics include, but are not limited to, the following:

  • Animal models of cardiovascular disease associated with hypertension;
  • Isolation and characterization of natural products with antihypertensive effects;
  • News synthetic drugs useful in the treatment of hypertension;
  • Preclinical and clinical trials of synthetic drugs and plant-derived medicines such as antihypertensive agents;
  • Systematic or narrative reviews of synthetic drugs and natural products with antihypertensive properties;
  • Synergistic effects of synthetic drugs and natural products on hypertension treatment.

Prof. Dr. Arquimedes Gasparotto Junior
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antihypertensive
  • cardioprotective
  • herbal medicine
  • hypertension
  • medicinal plants

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 3136 KiB  
Article
The Cardiorenal Effects of Piper amalago Are Mediated by the Nitric Oxide/Cyclic Guanosine Monophosphate Pathway and the Voltage-Dependent Potassium Channels
by Luciane M. Monteiro, Lislaine M. Klider, Aline A. M. Marques, Paulo V. Farago, Janaína Emiliano, Roosevelt I. C. Souza, Ariany C. dos Santos, Vera L. P. dos Santos, Mei Wang, Nadla S. Cassemiro, Denise B. Silva, Ikhlas A. Khan, Arquimedes Gasparotto Junior and Jane Manfron
Pharmaceuticals 2023, 16(11), 1630; https://doi.org/10.3390/ph16111630 - 20 Nov 2023
Viewed by 1355
Abstract
Piper amalago L. is used in Brazilian traditional medicine to treat inflammation, chest pain, and anxiety. This study aimed to investigate the safety and the renal and cardiovascular effects of the volatile oil (VO) and the aqueous (AE) and hydroalcoholic (HE) extracts from [...] Read more.
Piper amalago L. is used in Brazilian traditional medicine to treat inflammation, chest pain, and anxiety. This study aimed to investigate the safety and the renal and cardiovascular effects of the volatile oil (VO) and the aqueous (AE) and hydroalcoholic (HE) extracts from P. amalago. The gas chromatography-mass spectrometry analyses identified 47 compounds in the VO, with β-cyclogermacrene, spathulenol, β-phellandrene, and α-pinene standing out. Among the 47 compounds also found in AE and HE by liquid chromatography-mass spectrometry, glycosylated flavones, organic acids, amino acids, and amides were highlighted. Some examples of these compounds are methoxy-methylenedioxy cis-cinnamoyl pyrrolidine, methoxy-methylenedioxy trans-cinnamoyl pyrrolidine, and cyclobutene-2,4-bis-(1,3-benzodioxol-5-methoxy-6-yl)-1,3-dicarboxapyrrolidide. The acute toxicity experiments were conducted on female rats (n = 5). The cardiorenal assays (n = 8) and evaluations of vasodilatory effects on the mesenteric vascular bed (n = 5) were conducted on male rats. In either extract or VO, there were no mortality or changes in relative weights or histopathological analysis of the organs. Urinary volume and renal electrolyte excretion were elevated significantly during repeated dose 7-day treatment with different preparations from P. amalago. None of the preparations induced hypotension or changes in cardiac electrical activity. Only HE promoted significant vasodilatory effects in rats’ isolated mesenteric vascular beds. These effects were completely abolished in the presence of L-NAME plus 4-aminopyridine. Therefore, P. amalago leaves are safe and present diuretic activity after acute and repeated dose administration over 7 days. Moreover, the HE induced significant vasodilator response in rats’ mesenteric vascular beds by NO/cGMP pathway and voltage-dependent K+ channels activation. Full article
(This article belongs to the Special Issue Pharmacological Advances for Treatment in Hypertension 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 1503 KiB  
Review
Purinergic Receptor Antagonists: A Complementary Treatment for Hypertension
by Rocio Bautista-Pérez and Martha Franco
Pharmaceuticals 2024, 17(8), 1060; https://doi.org/10.3390/ph17081060 - 13 Aug 2024
Viewed by 807
Abstract
The treatment of hypertension has improved in the last century; attention has been directed to restoring several altered pathophysiological mechanisms. However, regardless of the current treatments, it is difficult to control blood pressure. Uncontrolled hypertension is responsible for several cardiovascular complications, such as [...] Read more.
The treatment of hypertension has improved in the last century; attention has been directed to restoring several altered pathophysiological mechanisms. However, regardless of the current treatments, it is difficult to control blood pressure. Uncontrolled hypertension is responsible for several cardiovascular complications, such as chronic renal failure, which is frequently observed in hypertensive patients. Therefore, new approaches that may improve the control of arterial blood pressure should be considered to prevent serious cardiovascular disorders. The contribution of purinergic receptors has been acknowledged in the pathophysiology of hypertension; this review describes the participation of these receptors in the alteration of kidney function in hypertension. Elevated interstitial ATP concentrations are essential for the activation of renal purinergic receptors; this becomes a fundamental pathway that leads to the development and maintenance of hypertension. High ATP levels modify essential mechanisms implicated in the long-term control of blood pressure, such as pressure natriuresis, the autoregulation of the glomerular filtration rate and renal blood flow, and tubuloglomerular feedback responses. Any alteration in these mechanisms decreases sodium excretion. ATP stimulates the release of vasoactive substances, causes renal function to decline, and induces tubulointerstitial damage. At the same time, a deleterious interaction involving angiotensin II and purinergic receptors leads to the deterioration of renal function. Full article
(This article belongs to the Special Issue Pharmacological Advances for Treatment in Hypertension 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop